The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of AK119, an anti-CD73 monoclonal antibody, in combination with AK104, an anti-PD-1/CTLA-4 bispecific antibody, in patients with advanced or metastatic solid tumors.
 
Ben Markman
Consulting or Advisory Role - Amgen; Amgen
Travel, Accommodations, Expenses - Akeso Biopharma
 
Amy Hsin-Chieh Hsieh
No Relationships to Disclose
 
Jermaine Coward
Research Funding - AstraZeneca (Inst)
 
Matteo S. Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; IDEAYA Biosciences; Merck Serono; MSD; Nektar; Novartis; OncoSec; Pierre Fabre; QBiotics; Regeneron; Roche; Sanofi
 
Sophia Frentzas
No Relationships to Disclose
 
Xiaoping Jin
Employment - Akeso Biopharma
Leadership - Akeso Biopharma
Stock and Other Ownership Interests - Akeso Biopharma
 
Baiyong Li
Employment - Akeso Biopharma
Leadership - Akeso Biopharma
Stock and Other Ownership Interests - Akeso Biopharma
 
Zhongmin Maxwell Wang
Employment - Akeso Biopharma
Leadership - Akeso Biopharma
Stock and Other Ownership Interests - Akeso Biopharma
 
Kon Yew Kwek
Employment - Akeso Biopharma
Stock and Other Ownership Interests - Akeso Biopharma
 
Yu Xia
Employment - Akeso Biopharma
Leadership - Akeso Biopharma
Stock and Other Ownership Interests - Akeso Biopharma